Profesor titular

Facultad de Medicina. Universidad de Chile.

Grados y Postgrados:

• Canesin G, Maggio V, Palominos M, Stiehm A, Contreras HR, Castellón EA, Morote J, Paciucci R, Maitland NJ, Bjartell A, Hellsten R. STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population Sci Rep. (2020) Aug 18;10(1):13958. doi: 10.1038/s41598 -020-70948-5. IF: 4,122
• Figueroa D, Signore A, Araneda O, Contreras HR, Concha M, García C. Toxicity and differential oxidative stress effects on zebrafish larvae following exposure to toxins from the okadaic acid group. J Toxicol Environ Health A. (2020) Aug 17;83(15-16):573-588. doi: 10.1080/15287394. (2020).1793046. Epub (2020) Jul 19. IF: 2,88
• Rivas J, Díaz N, Silva I, Morales D, Lavanderos B, Álvarez A, Saldías MP, Pulgar E, Cruz P, Maureira D, Flores G, Colombo A, Blanco C, Contreras HR, Jaña F, Gallegos I, Concha ML, Vergara-Jaque A, Poblete H, González W, Varela D, Trimmer JS, Cáceres M, Cerda O. KCTD5, a novel TRPM4-regulatory protein required for cell migration as a new predictor for breast cancer prognosis. FASEB J. (2020) Apr 17. doi: 10.1096/fj.(2019) Online ahead of print. IF: 5,391
• Jimenez-Cárcamo D, García C, Contreras HR. Toxins of Okadaic Acid OA-Group Increase Malignant Properties in Cells of Colon Cancer. Toxins (Basel). (2020) Mar 13;12(3):179. doi: 10.3390/toxins1203017. IF: 3,897
• Contreras HR, López-Moncada F, Castellón, EA. Cancer stem cells and mesenchymal cells cooperative action in metastasis progression and hormone resistance in prostate cancer: Potential role of stemness genes, androgen and GnRH receptors. (2020) International Journal of Oncology May;56(5):1075-1082. doi: 10.3892/ijo.(2020).5008. Epub (2020) Mar 5.Int J Oncol. (2020).PMID: 32319606 IF: 3.45
• Farfán N, Orellana-Serradell O, Herrera D, Chrzanowsky D, Cubillos P, Marín G, Antonio García De Herreros A, Castellón EA, Contreras HR. SNAIL expression correlates with the translocation of Syndecan 1 intracellular domain into the nucleus in prostate cancer cell lines. International Journal Molecular Medicine (2020) Apr;45(4):1073-1080. doi: 10.3892/ijmm.(2020).4488. Epub (2020) Feb 5. IF: 2.996
• Campolina-Silva GH, Werneck-Gomes H, Barata MC, Torres MJ, Contreras HR, Germán A. B. Mahecha, Cleida A. Oliveira. Targeting Wistar rat as a model for studying benign, premalignant and malignant lesions of the prostate. Life Sci. (2020) Feb 1; 242:117149. doi: 10.1016/j.lfs.(2019). 117149. Epub (2019) Dec 9. IF: 3.448
• Aedo-Aguilera V, Carrillo-Beltrán D, Calaf GM, Muñoz JP, Guerrero N, Osorio JC, Tapia JC, León O, Contreras HR, Aguayo F. Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells. Oncol Rep. (2019) Aug 21. doi: 10.3892/or.(2019).7288. IF: 3.041
• Landskron G, De la Fuente López M, Dubois-Camacho K, Díaz-Jiménez D, Orellana-Serradell O, Romero D, Sepúlveda SA, Salazar C, Parada-Venegas D, Quera R, Simian D, González MJ, Kronberg U, Abedrapo M, Gallegos I, Contreras HR, Peña C, Díaz-Araya G, Roa JC, Hermoso MA. Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer. Front Immunol. (2019) Jun 21; 10:1394. doi: 10.3389/fimmu.(2019).01394. eCollection (2019). IF: 4,716
• Lopez-Moncada F, Torres MJ, Castellón EA, Contreras HR. Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer. Asian J Androl. (2019) Nov-Dec;21(6):557-564. doi: 10.4103/aja.aja_23_19. IF: 3,259
• Orellana-Serradell O, Herrera D, Castellón EA, Contreras HR. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines. Asian J Androl. (2019) Mar 15. doi: 10.4103/aja.aja_1_19. [Epub ahead of print] IF: 3,259
• Contreras HR, García. Inter-species variability of okadaic acid group toxicity in relation to the content of fatty acids detected in different marine vectors. C. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. (2019) Mar; 36(3):464-482. doi: 10.1080/19440049. (2019).1569265. Epub (2019) Feb 6. IF: 2,170
• Farfán N, Ocarez N, Castellón EA, Mejía N, de Herreros AG, Contreras HR. The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer. Sci Rep. (2018) Jul 31;8(1) :11467. doi: 10.1038/s41598-018-29829-1. IF: 4,122
• Herrera D, Orellana-Serradell O, Villar P, Torres MJ, Paciucci R, Castellón EA, Contreras HR. Silencing of the transcriptional factor ZEB1 alters the steroidogenic pathway and increases the concentration of testosterone and DHT in DU145 cells. Oncol Rep. (2019) Feb;41(2):1275-1283. doi: 10.3892/or.(2018).6885. Epub (2018) Nov 26. IF: 3.041
• Orellana-Serradell O, Herrera D, Castellon EA, Contreras HR. The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines. Asian J Androl. (2017) Dec 19. doi: 10.4103/aja.aja_61_17. ISSN: 1745-7262. IF: 2.996
• Oyaneder Terrazas J, Contreras HR, García C. Prevalence, Variability and Bioconcentration of Saxitoxin-Group in Different Marine Species Present in the Food Chain. Toxins (Basel). (2017) Jun 12;9(6). pii: E190. doi: 10.3390/toxins9060190. IF: 3,897
• Sánchez C, Contreras HR, Gallegos I, Ito T, Eishi Y, Fulla J, Ramos C. First Report of Propionibacterium acnes in Prostate from Chilean Patients. Clin Oncol 1: 1143. (2016).
• García C, Oyaneder-Terrazas J, Contreras C, Del Campo M, Torres R, Contreras HR. Determination of the toxic variability of lipophilic biotoxins in marine bivalve and gastropod tissues treated with an industrial canning process. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. (2016) Nov;33(11):1711-1727. Epub (2016) Oct 11. IF: 2.170
• Osorio LA, Farfán NM, Castellón EA, Contreras HR. SNAIL transcription factor increases the motility and invasive capacity of prostate cancer cells. Mol Med Rep. 13(1):778-86 ((2016)). ISSN: 1791-2997. IF: 1.851
• Hager Ribeiro C, Kramm K, Gálvez-Jirón F, Pola V, Bustamante M, Contreras HR, Sabag A, Garrido-Tapia M, Hernández C, Zúñiga R, Collazo N, Sotelo P, Morales C, Mercado L, Catalán D, Aguilón JC. and Molina MC. Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients. Oncology Report (2016) Mar; 35(3):1309-17. doi: 10.3892/or.(2015).4510. Epub (2015) Dec 23. IF: 3.041
• Cifuentes F, Valenzuela R, Contreras HR, Castellón EA. Surgical cytorreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol. Rep. 34(6):2837-44 (2015). ISSN: 1021-335X. IF: 3.041
• Cifuentes F, Valenzuela R, Contreras HR, Castellón EA. Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCIDγ mouse (Mus musculus) anterior prostate. Oncol. Lett. 10(4):2142-2148 (2015). ISSN: 1792-1074. IF: 1.871
• Orellana-Serradell O, Poblete CE, Sanchez C, Castellón EA, Gallegos I, Huidobro C, Llanos MN, Contreras HR. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep. 33(4):1599-608. (2015) doi: 10.3892/or.(2015).3746. ISSN: 1021-335X. IF: 3.041
• García, C., Pérez, F., Contreras, C., Figueroa, D., Barriga, A., López-Rivera, A., Araneda, OF., Contreras, HR. (2015). “Saxitoxins and okadaic acid group: accumulation and distribution in invertebrate marine vectors from Southern Chile”. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. (2015) Apr 15:1-19. [Epub ahead of print]. IF: 2.170
• Castillo V, Valenzuela R, Huidobro C, Contreras HR, Castellon EA. Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol. 45(3):985-94. (2014). doi: 10.3892/ijo. (2014).2529. ISSN: 1019-6439. IF: 3.025.
• Poblete CE, Fulla J, Gallardo M, Muñoz V, Castellón EA, Gallegos I, Contreras HR. Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer. Int J Oncol. 44(3):647-54. (2014). doi: 10.3892/ijo.(2014).2254. SSN: 1019-6439. IF: 3.45
• Marqués N., Sesé M., Cánovas V., Valente F., Bermudo R., de Torres I., Fernández Y., Abasolo I., Fernández P., Contreras HR., Castellón EA., Celià-Terrassa T., Méndez R., Ramón y Cajal S., Thomson T., Paciucci R. Regulation of protein translation and c-Jun expression by Prostate Tumor Overexpressed 1. Oncogene. 33(9):1124-34. (2014). doi: 10.1038/onc.51. ISSN: 0950-9232. IF: 8.469
• Castellón EA., Valenzuela R., Lillo J., Castillo V., Contreras HR., Gallegos I., Mercado A., Huidobro C. Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis. Biol. Res. 45: 99-107 (2012). IF: 2.357.
• Sánchez C., Mercado A., Contreras HR., Cabezas J., Huidobro C., Castellón EA. Pharmacoperone IN3 enhances apoptotic effect of leuprolide in prostate cancer by increasing GnRH receptor in cell membrane. Anti-Cancer Drugs. 23(9): 959-69 (2012)
• Sánchez C., Mercado A., Contreras HR., Mendoza P., Cabezas J., Acevedo C., Huidobro C., Castellón EA. Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. Prostate 71(16): 1810-7 (2011)
• Ledezma R., Cifuentes F., Gallegos I., Fullá J., Ossandón E., Castellón EA., Contreras HR. Shift of expression pattern of syndecans 1 and 2 predicts biochemical recurrence in prostate cancer. Asian J. Androl. 13(3): 476-480. (2011)
• Mercado A., Sánchez C., Fullá J., Ledezma R., Acevedo C., Cabezas J., Huidobro C., Contreras HR., Castellón EA. Expresión y actividad de proteínas de multirresistencia a drogas (MDR) en líneas celulares de cáncer de próstata. Rev. Chil. Urol. 75(1): 25-30. (2010)
• Contreras HR., Ledezma R. Vergara J., Cifuentes F., Barra C., Gallegos I., Morales B., Huidobro C. and Castellón EA. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol. 28(5): 534-40. (2010).

* 2017-2019.  Investigador Responsable Proyecto U-Redes de Consolidación Titulo: DiNaC: Identificación de nuevas dianas terapéuticas y desarrollo de nanoformulaciones para el tratamiento cánceres de alta mortalidad en Chile.

* 2016-2019.  Co-Investigador Proyecto FONDECYT  1160168 Título: Toxicological effects of lipophilic toxins produced by harmful algal blooms on farmed (Salmon salar) and endemic fishes (Merluccius australis and Genypterus chilensis) in austral fjords from the Aysén region. Investigador Responsible: Carlos García.

* 2015-2018 Investigador Responsable Proyecto FONDECYT Nº 1151214  Título: «The transcription factors Zeb1/Snail induce in vitro cell malignancy and cancer stem cell phenotype through epithelial- mesenchymal transition in prostate cells, increasing androgen synthesis capacity and resistance».  2015-2017 Co-Investigador Proyecto del Ministerio de Economia (MINECO). España. Título: “The therapeutic stress as generator of resistance in prostate cancer stem cells: predictive markers of resistance and therapeutic targets». Investigador Responsable: Dra. Rosanna Paciucci.

* 2012-2014.  Coinvestigador Proyecto FONDEQUIP 2012  Titulo: Mejoramiento de las capacidades de la Unidad de Microscopía Avanzada (Microscopía Confocal) Investigador Responsable: Dr. Christian González..

* 2014-2017.  Coinvestigador Proyecto FONDECYT Nº 1140417 Título: «Cancer stem cells and mesenchymal cells cooperative action  in metastasisprogression and hormone resistance in prostate cancer: Role of stemness genes, androgen and GnRH receptors». Investigador Responsable: Dr. Enrique Castellón.

* 2011-2015.  Investigador Responsable Proyecto FONDECYT Nº 1110269 Título: “Expression of syndecans is down regulated by transcriptional factor snail during epithelial mesenchymal transition in prostate cancer”. 

* 2011-2013.  Coinvestigador Proyecto U-Redes. Programa Consolidación de Redes. Vicerrectoría de Investigación y Desarrollo (VID). Universidad de Chile. Título: “Red de Medicina Traslacional en Cáncer”. Investigador Responsable: Dr. Ricardo Armisen 

* 2011-2012.  Coinvestigador Proyecto U-Moderniza U-MOD-02. Vicerrectoría de Investigación y Desarrollo (VID). Universidad de Chile. Título: “In vivo bioluminiscence and fluorescence models applied to vanguard biomedical research”. Investigador Responsable: Dr. Enrique Castellón y  Dr. Julio Tapia. 

* 2010-2014.  Coinvestigador Proyecto FONDECYT Nº 1100183 Título: “Study on the presence and characteristics of cancer stem cells in human prostate cancer. Isolation characterization and in vitro recovery of sensitivity to hormone and chemotherapy”. Investigador Responsable: Dr. Enrique Castellón.

* 2009-2010.  Coinvestigador Proyecto AECI Nº A/016762/08 Título: “Estudio fenotipico de células madre neoplásicas y de su transición epitelio-mesenquima en muetras exvivo derivadas de adenocarcinomas prostáticos humanos”.